A week full of economic data sent the markets lower. Monday's Institute for Supply Management report started things off on the negative foot, and then factory orders came on Tuesday, which showed signs of both strength and weakness in the economy. Then on Wednesday, Thursday, and Friday, investors were hit by one poor jobs report after another. And after ending last week on a high note, with the S&P 500 hitting a new record high, investors ended this week thinking the economy looks rather weak in its current stage.
And with that, the Dow Jones Industrial Average (DJINDICES: ^DJI ) ended the week down 13 points, or 0.09%, and now sits at 14,578. The S&P 500 performed slightly worse, as it lost 15 points, or 1.01%, and the Nasdaq had its worst week of 2013, losing 63 points, or 1.94%.
Although the Dow lost during the week, its components were split down the middle -- half moved higher, while half headed lower.
Before we hit the Dow losers, let's look at the index's big winner of the week. After rising 5.05% two weeks ago, shares of UnitedHealth Group rose another 8.5% this past week. The main reason for the increase was the announcement on Monday that reversed the previously planned 2.2% cut to the Medicare Advantage payout and instead raised it by 3.3%. This turnaround should help not only UnitedHealth but also all the insurance providers.�
Hot Gas Utility Companies To Own In Right Now: Goldsearch Ltd (GSE)
Goldsearch Limited (Goldsearch) is an Australia-based minerals company. During the fiscal year ended June 30, 2012 (fiscal 2012), the Company was engaged in the exploration of gold and other minerals and investment activities. It operates in five segments: Mineral Exploration Sweden, Minerals Exploration Australia-Victoria, Minerals Exploration Australia-Other, Investments and Administration. Its other projects include the Mary Kathleen joint venture in Queensland and the Musgrave joint venture in South Australia. It held 16,000 square kilometres of tenements within the Musgrave Ranges of northwestern South Australia that were in joint venture between Goldsearch and Independence Group. During fiscal 2012, the Company held investments in Morning Star Gold NL (MCO) and Musgrave Minerals Ltd (MGV). On June 30, 2012, the Company had sold off its total investment in Independence Group NL (IGO). Its subsidiaries include: Caytale Pty Limited, Chiljill Pty Limited and Miltonpak Pty Limited. Advisors' Opinion:- [By Roberto Pedone]
Another environmental services player that looks ready to trigger a near-term breakout trade is GSE Holdings (GSE), which provides geosynthetic containment solutions for environmental protection and confinement applications. This stock has been hammered by the bears so far in 2013, with shares down big by 55%.
If you take a look at the chart for GSE Holdings, you'll notice that this stock recently ripped sharply higher back above its 50-day moving average of $2.32 a share with heavy upside volume. Following that move, shares of GSE have started to trend sideways between $2.60 on the downside and $2.95 on the upside. Shares of GSE are now starting to move within range of triggering a near-term breakout trade above the upper-end of its recent range.
Traders should now look for long-biased trades in GSE if it manages to break out above some near-term overhead resistance levels at $2.79 to $2.95 a share with high volume. Look for a sustained move or close above those levels with volume that hits near or above its three-month average action of 221,545 shares. If that breakout hits soon, then GSE will set up to re-test or possibly take out its next major overhead resistance levels at $3.50 to $4 a share.
Traders can look to buy GSE off any weakness to anticipate that breakout and simply use a stop that sits right below support at $2.60 or below its 50-day moving average at $2.32 a share. One could also buy GSE off strength once it takes out those breakout levels with volume and then simply use a stop that sits a comfortable percentage from your entry point.
Best Rising Companies To Watch For 2014: Juniper Networks Inc (JNPR)
Juniper Networks, Inc. (Juniper Networks), incorporated on September 10, 1996, designs, develops, and sells products and services that together provide its customers with network infrastructure. It operates in two segments: Infrastructure and Service Layer Technologies (SLT). The Company�� Infrastructure segment primarily offers routing and switching products that are used to control and direct network traffic from the core, through the edge, aggregation, and the customer premise equipment level. Infrastructure products include its Internet protocol (IP) routing, carrier Ethernet routing portfolio, and Ethernet switching portfolio. In addition, the Infrastructure segment offers a complete wireless local area network (WLAN) solution. Its SLT segment offers solutions that meet a range of its customers' priorities, from protecting the users, applications and data on the network itself to providing network services across a distributed infrastructure. Effective September 13, 2013, Juniper Networks, Inc. acquired Contrail Networks Inc.
Brilliant is a supplier of packet-based, network synchronization equipment and monitoring solutions. During the year ended December 31, 2011, the Company introduced its network architecture and fabric technology for the data center, QFabric. It serves the high-performance networking requirements of global service providers, enterprises, and public sector organizations. The Company�� open cross-network software platform includes the Junos operating system (Junos OS), Junos Space network application platform, and Junos Pulse integrated network client. The Company offers a product portfolio that spans routing, switching, security, application access, and mobility device security.
Infrastructure Products
The Company�� T Series core routers are primarily designed for core IP infrastructures and are also being sold into the multi-service environment. Its PTX Series is a large capacity (8 and 16 tera-bits per second) MPLS-optimized packe! t transport switch for the core networks, of content service providers and Tier 1 service providers, with high throughout of packet traffic. The Company�� E Series products are a full featured platform designed for the network edge with support for carrier-class routing, broadband subscriber management services, and a set of IP services. The MX Series is a product family developed to address emerging Ethernet network architectures and services in service provider and enterprise networks. The Company�� EX Series family extends its product portfolio running its Junos OS to address the Ethernet switch market. Ethernet is a used technology, which is used to transport information in enterprise networks. Infrastructure Products also includes QFabric Products and WLAN product.
SLT Products
SLT Products include Services Gateway, Integrated Firewall, and VPN Solutions, Secure Access Appliances, Secure Access Appliances, IDP Series Appliances and Identity and Policy Control Solutions. The Company�� SRX Series of dynamic services gateways, running its Junos software, provides firewall/VPN and combines routing, switching, and security functionality. The series is designed to meet network and security requirements for data center consolidation, rapid managed services deployments, and aggregation of security services. Its firewall and VPN systems and appliances are designed to provide integrated firewall, VPN, and denial of service protection capabilities for both enterprise environments and service provider network infrastructures. These products range from its SSG product series, which combines LAN/WAN routing capabilities with threat management features, such as antivirus, anti-spam, and Web filtering technologies, to its ISG and NetScreen Series firewall and VPN systems, which are designed to deliver security in medium/large enterprises, carrier networks, and data centers.
The Company�� Junos Pulse, Junos Pulse Mobile Security Suite, and SA Series SSL VPN appliances,! designed! for use in companies of all sizes, are used to provide secure access to corporate resources for remote and mobile users from any Web-enabled device, regardless of location. Its portfolio of identity and policy control solutions integrates subscriber privileges, application requirements, and business policies with the IP network infrastructure.
The Company competes with Cisco Systems, Inc. (Cisco), Alcatel-Lucent, Brocade Communications Systems, Inc. (Brocade), Extreme Networks, Inc., Hewlett Packard Company (HP), Huawei Technologies Co., Ltd. (Huawei), Check Point Software Technologies, F5 Networks, Inc., Palo Alto Networks, Inc., and Riverbed Technology, Inc.
Advisors' Opinion:- [By Wallace Witkowski]
Juniper Networks Inc. (JNPR) �is forecast to post adjusted fourth-quarter earnings of 37 cents on revenue of $1.22 billion.
- [By Jake L'Ecuyer]
Equities Trading UP
Juniper Networks (NYSE: JNPR) shot up 6.85 percent to $27.79 after the company reported better-than-expected fourth-quarter results. Barclays upgraded the stock from Equalweight to Overweight and lifted the price target from $29.00 to $34.00. - [By Jon C. Ogg]
Juniper Networks, Inc. (NYSE: JNPR) managed to hit another annual high of $28.75, and closed on Friday up just over 6.5% at $27.72. That 38 million shares stands out heavily as well, considering that the average volume is almost 9 million share per day. Juniper also saw at least three key analyst upgrades as well. Having 59% quarterly profit growth is not the norm in this market, and Jana Capital is actively pressing the company to do better in managing costs and returning capital to holders. Juniper has about $4 billion in cash and liquidity (versus what is now a $14 billion market cap), yet it pays no dividend. Our quick calculation of a 25% payout of adjusted operating earnings ahead would yield a dividend of about 1.4% without Juniper eating into its huge treasure chest already on the books.
- [By Monica Wolfe]
The following information is a highlight of the real-time guru activity we saw this week. To view more information on these gurus, check out their guru portfolios. The ��eal Time Picks��reports the stock purchases and sells that Gurus have made within the prior two weeks. If a Guru makes a purchase or sell of a company in which they own a greater-than 5% stake, SEC regulations require them to report their transaction within two days. This week we saw notable increases and buys in Real Time activity from Kyle Bass (Trades, Portfolio) and Paul Singer (Trades, Portfolio).Kyle Bass (Trades, Portfolio) Over the past week Kyle Bass (Trades, Portfolio) made a notable increase in to Nationstar Mortgage Holdings (NSM). The guru added a total of 3,673,972 shares of the company�� stock. He bought these shares at an average price of $31.27 per share, and since then the price per share has gone up about 5% to $32.80 per share.Bass now holds on to 4,759,610 shares of Nationstar Mortgage holdings, representing 5.26% of the company�� shares outstanding.Bass�� historical holding history as of the close of the fourth quarter 2013:Nationstar Mortgage provides residential mortgage loan services. It services residential mortgage loans throughout the United States. Nationstar is one of the largest servicers in the US, with a residential mortgage servicing portfolio of over $391 billion in unpaid principal balance as of Dec. 31, 2013.Nationstar Mortgage�� historical revenue and net income:The company recently released its fourth quarter and full year financial results which highlighted:- 2013 GAAP EPS of $2.40 on net income of $217 million.- Ending servicing portfolio UPB of $391 billion.- 2013 servicing portfolio growth of 88%.- 2013 return on equity of 25%.- Funded volume of $24 billion in 2013.The company also recently announced that they had received a letter from Benjamin Lawsky, Superintendent of the New York Department of Financial Services, which inquires about Nat
Best Rising Companies To Watch For 2014: Roche Holding AG (RHHBY)
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.
During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.
In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.
Pharmaceuticals
Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.
Diagnostics
Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.
Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.
Advisors' Opinion:- [By James E. Brumley]
I hate to be the one to say I told you so, but, I told you so. Back on February 26th I suggested IsoRay, Inc. (NYSEMKT:ISR) shares were a budding breakout play. The 48% rally that's played out for ISR in the meantime unfurled right on cue. While overbought in the very short run, this small cap stock looks like it's earning the right to be compared to the likes of bigger brothers in the cancer-treatment space... names like Roche Holding Ltd. (OTCMKTS:RHHBY) or Theragenics Corporation (NYSE:TGX).
- [By James Brumley]
Ditto for the gene-mapping mania that was sparked by the Roche (RHHBY) acquisition of Illumina and the GlaxoSmithKline (GSK) purchase of Human Genome Sciences. By the time the gene-mapping M&A trend became obviously hot, the trend was over.
Best Rising Companies To Watch For 2014: Spdr S&P Semiconductor Etf (XSD)
SPDR S&P Semiconductor ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Semiconductor Select Industry Index. The S&P Semiconductor Select Industry Index represents the Semiconductor sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges. The Semiconductor Index is a modified equal weight index. SSgA Funds Management, Inc. is the Fund's investment advisor. Advisors' Opinion:- [By John Udovich]
On Thursday after the market closed, mid cap fabless semiconductor stock Marvell Technology Group Ltd (NASDAQ: MRVL) reported earnings and was slipping in after hours trading, meaning its worth taking a closer look at those earnings along with the performance of potential semiconductor benchmarks like the SPDR S&P Semiconductor ETF (NYSEARCA: XSD), iShares PHLX SOX Semiconductor Sector (NASDAQ: SOXX) and Direxion Daily Semiconductor Bull 3X Shares (NYSEARCA: SOXL). In case you aren�� familiar with the term fabless semiconductor, it�� a�business�model that involves the�outsourcing the manufacturing of silicon wafers.�Most semiconductor companies are actually fabless because of the high cost of building�a facility and manufacturing fab. Therefore, fabless semiconductor companies can�concentrate on the design and marketing of chips while outsourcing the actual production to larger foundry companies.
Best Rising Companies To Watch For 2014: Accuray Incorporated(ARAY)
Accuray Incorporated designs, develops, and sells medical radiation systems for the treatment of tumors anywhere in the body. The company offers the CyberKnife system, an image-guided robotic radiosurgery system used for the treatment of solid tumors. The system tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation typically with sub-millimeter accuracy. The company also offers the TomoTherapy system, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. Accuray Incorporated markets its product through a direct sales force and distributors worldwide. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
Advisors' Opinion:- [By John Udovich]
Small cap robotic stock Adept Technology (NASDAQ: ADEP) has put in a very good performance this month verses its immediate peer�iRobot Corporation (NASDAQ: IRBT) as well as against medical robotic stocks like MAKO Surgical (NASDAQ: MAKO), Accuray Incorporated (NASDAQ: ARAY) and Hansen Medical, Inc (NASDAQ: HNSN). I should also mention that we have recently added Adept Technology to our SmallCap Network Elite Opportunity (SCN EO) portfolio (we are up 9% since last week) because we feel robotics is an improving sector as companies aim to reduce overhead and improve efficiencies through machine to machine (M2M) automation.
- [By John Kell]
Accuray Inc.(ARAY) shares jumped after the company posted a narrower loss than expected in its fiscal second quarter and raised its revenue estimate for the year. Shares rose 9.1% to $10.08 premarket.
- [By Sean Williams]
What: Shares of Accuray (NASDAQ: ARAY ) , a designer of medical radiation systems for the treatment of cancer, jumped as much as 14% after reporting its fourth-quarter earnings results.
- [By Ben Levisohn]
Accuray (ARAY) has gained 2.7% to $9.03 after the surgical-device maker was upgraded to Overweight from Neutral at JPMorgan.
Brady (BRC) has gained 1.7% to $28.38 after it was upgraded to Buy from Underperform at Merill Lynch.
Best Rising Companies To Watch For 2014: Connecticut Water Service Inc. (CTWS)
Connecticut Water Service, Inc., through its subsidiaries, operates as a regulated water company in Connecticut. It operates in three segments: Water Activities, Real Estate Transactions, and Services and Rentals. The Water Activities segment supplies drinking water. The Real Estate Transactions segment involves in the sale or donation of its real estate holdings. The Services and Rentals segment provides contracted services to water and wastewater utilities and other clients, which include contract operations of water and wastewater facilities; Linebacker, an optional service line protection program that comprises repairing or replacing leaking or broken water service line, curb box, curb box cover, meter pit, meter pit cover, meter pit valve, and in-home water main shut off valve before the meter; and providing bulk deliveries of emergency drinking water to businesses and residences through tanker trucks. This segment also engages in leasing and renting residential and c ommercial properties. As of December 31, 2009, Connecticut Water Service, Inc. served 88,534 customers in 54 towns in Connecticut. The company was founded in 1956 and is headquartered in Clinton, Connecticut.
Advisors' Opinion:- [By David Dittman]
Question: I like the H2O business. I��e owned American Water Works Co Inc (NYSE: AWK) for eons. Is there any compelling reason to own more than one water utility? At what point does is there no marginal benefit added? I do like Connecticut Water Service Inc (NSDQ: CTWS) and York Water Co (NSDQ: YORW) as slow, consistent growers.
As Ben Franklin said, ��ittle strokes fell great oaks.��/p>
Best Rising Companies To Watch For 2014: Air Methods Corporation(AIRM)
Air Methods Corporation, together with its subsidiaries, provides air medical emergency transport services and systems in the United States. It transports persons requiring intensive medical care from either the scene of accident or general care hospitals to highly skilled trauma centers or tertiary care centers. The company operates through three segments: Community-Based Services, Hospital-Based Services, and United Rotorcraft. The Community-Based Services segment provides air medical transportation services, including aircraft operation and maintenance, medical care, dispatch and communications, and medical billing and collection services. This segment operates 201 helicopters and 15 fixed wing aircraft in 29 states. The Hospital-Based Services segment offers air medical transportation services, and medically equipped helicopters and airplanes for hospitals. It operates 212 helicopters and 6 fixed wing aircraft in 34 states. The United Rotorcraft segment designs, manufa ctures, installs, and certifies modular medical interiors, multi-mission interiors, and other aerospace and medical transport products for domestic and international customers, as well as provides quality assurance and certification services. Air Methods Corporation was founded in 1982 and is headquartered in Englewood, Colorado.
Advisors' Opinion:- [By Ali Berri]
Shares of Air Methods (NASDAQ: AIRM) got a boost, shooting up 8.91 percent to $57.93 on upbeat quarterly results.
NVIDIA (NASDAQ: NVDA) shares were also up, gaining 7.62 percent to $18.79 after the company posted higher Q2 earnings and issued a strong revenue forecast for the current quarter.
No comments:
Post a Comment